Viking Therapeutics, Inc. (VKTX) Scorecard
- 2026-Q2: Total return Win; Revenue growth Lose; EPS growth Win.
- 2026-Q1: Total return Lose; Revenue growth Lose; EPS growth Win.
- 2025-Q4: Total return Win; Revenue growth Lose; EPS growth Win.
- 2025-Q3: Total return Lose; Revenue growth Lose; EPS growth Win.
30/120
All 120 Win/Lose results shown below
Every strict quarterly win earns 1 point. A loss, tie, or unavailable scoring value earns 0.
Trailing 1 year (4 quarters): 6 wins, 6 lossesLast fetched: 4 Sept 2026
Complete point ledger
Each cell identifies the missing side explicitly.
| Quarter | Total return | Revenue growth | EPS growth |
|---|---|---|---|
| 2026-Q22/3 |
WinVKTX / S&P 19.88% / 15.20% |
LoseVKTX / S&P VKTX unavailable / 15.00% |
WinVKTX / S&P 205.23% / 50.40% |
| 2026-Q11/3 |
LoseVKTX / S&P -7.50% / -4.33% |
LoseVKTX / S&P VKTX unavailable / 11.30% |
WinVKTX / S&P 260.87% / 27.70% |
| 2025-Q42/3 |
WinVKTX / S&P 33.87% / 2.65% |
LoseVKTX / S&P VKTX unavailable / 9.00% |
WinVKTX / S&P 219.00% / 13.40% |
| 2025-Q31/3 |
LoseVKTX / S&P -0.83% / 8.12% |
LoseVKTX / S&P VKTX unavailable / 4.61% |
WinVKTX / S&P 127.96% / 13.45% |
| 2025-Q21/3 |
LoseVKTX / S&P 9.73% / 10.94% |
LoseVKTX / S&P VKTX unavailable / 4.83% |
WinVKTX / S&P 62.77% / 10.63% |
| 2025-Q11/3 |
LoseVKTX / S&P -39.99% / -4.27% |
LoseVKTX / S&P VKTX unavailable / 4.98% |
WinVKTX / S&P 23.66% / 10.57% |
| 2024-Q41/3 |
LoseVKTX / S&P -36.44% / 2.41% |
LoseVKTX / S&P VKTX unavailable / 5.25% |
WinVKTX / S&P 8.70% / 6.15% |
| 2024-Q31/3 |
WinVKTX / S&P 19.43% / 5.89% |
LoseVKTX / S&P VKTX unavailable / 5.89% |
LoseVKTX / S&P 0.00% / 6.11% |
| 2024-Q20/3 |
LoseVKTX / S&P -35.35% / 4.28% |
LoseVKTX / S&P VKTX unavailable / 5.38% |
LoseVKTX / S&P 3.30% / 5.12% |
| 2024-Q11/3 |
WinVKTX / S&P 340.62% / 10.56% |
LoseVKTX / S&P VKTX unavailable / 5.71% |
LoseVKTX / S&P -2.11% / 5.59% |
| 2023-Q41/3 |
WinVKTX / S&P 68.11% / 11.69% |
LoseVKTX / S&P VKTX unavailable / 6.81% |
LoseVKTX / S&P 1.10% / 7.78% |
| 2023-Q31/3 |
LoseVKTX / S&P -31.71% / -3.27% |
LoseVKTX / S&P VKTX unavailable / 7.52% |
WinVKTX / S&P 14.81% / -5.03% |
| 2023-Q21/3 |
LoseVKTX / S&P -2.64% / 8.74% |
LoseVKTX / S&P VKTX unavailable / 9.50% |
WinVKTX / S&P 18.18% / -8.57% |
| 2023-Q12/3 |
WinVKTX / S&P 77.13% / 7.50% |
LoseVKTX / S&P VKTX unavailable / 10.77% |
WinVKTX / S&P 28.38% / -15.69% |
| 2022-Q41/3 |
WinVKTX / S&P 245.59% / 7.56% |
LoseVKTX / S&P VKTX unavailable / 11.88% |
LoseVKTX / S&P VKTX unavailable / -17.99% |
| 2022-Q30/3 |
LoseVKTX / S&P -5.88% / -4.88% |
LoseVKTX / S&P VKTX unavailable / 13.47% |
LoseVKTX / S&P VKTX unavailable / -1.41% |
| 2022-Q21/3 |
WinVKTX / S&P -3.67% / -16.10% |
LoseVKTX / S&P VKTX unavailable / 13.71% |
LoseVKTX / S&P VKTX unavailable / 11.04% |
| 2022-Q10/3 |
LoseVKTX / S&P -34.78% / -4.60% |
LoseVKTX / S&P VKTX unavailable / 15.97% |
LoseVKTX / S&P VKTX unavailable / 42.23% |
| 2021-Q40/3 |
LoseVKTX / S&P -26.75% / 11.03% |
LoseVKTX / S&P VKTX unavailable / 15.00% |
LoseVKTX / S&P VKTX unavailable / 96.40% |
| 2021-Q31/3 |
WinVKTX / S&P 4.84% / 0.58% |
LoseVKTX / S&P VKTX unavailable / 10.77% |
LoseVKTX / S&P VKTX unavailable / 69.42% |
| 2021-Q20/3 |
LoseVKTX / S&P -5.30% / 8.55% |
LoseVKTX / S&P VKTX unavailable / 6.58% |
LoseVKTX / S&P VKTX unavailable / 51.81% |
| 2021-Q11/3 |
WinVKTX / S&P 12.34% / 6.17% |
LoseVKTX / S&P VKTX unavailable / -1.06% |
LoseVKTX / S&P VKTX unavailable / 7.39% |
| 2020-Q40/3 |
LoseVKTX / S&P -3.26% / 12.15% |
LoseVKTX / S&P VKTX unavailable / -3.72% |
LoseVKTX / S&P VKTX unavailable / -33.42% |
| 2020-Q30/3 |
LoseVKTX / S&P -19.28% / 8.93% |
LoseVKTX / S&P VKTX unavailable / -2.04% |
LoseVKTX / S&P VKTX unavailable / -27.10% |
| 2020-Q21/3 |
WinVKTX / S&P 54.06% / 20.54% |
LoseVKTX / S&P VKTX unavailable / -0.46% |
LoseVKTX / S&P VKTX unavailable / -27.11% |
| 2020-Q10/3 |
LoseVKTX / S&P -41.65% / -19.60% |
LoseVKTX / S&P VKTX unavailable / 3.47% |
LoseVKTX / S&P VKTX unavailable / -14.75% |
| 2019-Q41/3 |
WinVKTX / S&P 16.57% / 9.07% |
LoseVKTX / S&P VKTX unavailable / 5.36% |
LoseVKTX / S&P VKTX unavailable / 2.99% |
| 2019-Q30/3 |
LoseVKTX / S&P -17.11% / 1.70% |
LoseVKTX / S&P VKTX unavailable / 5.02% |
LoseVKTX / S&P VKTX unavailable / 0.21% |
| 2019-Q20/3 |
LoseVKTX / S&P -16.50% / 4.30% |
LoseVKTX / S&P VKTX unavailable / 6.64% |
LoseVKTX / S&P VKTX unavailable / 8.65% |
| 2019-Q11/3 |
WinVKTX / S&P 29.93% / 13.65% |
LoseVKTX / S&P VKTX unavailable / 8.12% |
LoseVKTX / S&P VKTX unavailable / 14.29% |
| 2018-Q40/3 |
LoseVKTX / S&P -56.08% / -13.52% |
LoseVKTX / S&P VKTX unavailable / 9.05% |
LoseVKTX / S&P VKTX unavailable / 18.23% |
| 2018-Q31/3 |
WinVKTX / S&P 83.56% / 7.71% |
LoseVKTX / S&P VKTX unavailable / 10.21% |
LoseVKTX / S&P VKTX unavailable / 19.06% |
| 2018-Q21/3 |
WinVKTX / S&P 117.16% / 3.43% |
LoseVKTX / S&P VKTX unavailable / 9.03% |
LoseVKTX / S&P VKTX unavailable / 14.46% |
| 2018-Q11/3 |
WinVKTX / S&P 7.64% / -0.76% |
LoseVKTX / S&P VKTX unavailable / 7.68% |
LoseVKTX / S&P VKTX unavailable / 12.46% |
| 2017-Q41/3 |
WinVKTX / S&P 112.57% / 6.64% |
LoseVKTX / S&P VKTX unavailable / 7.03% |
LoseVKTX / S&P VKTX unavailable / 13.82% |
| 2017-Q31/3 |
WinVKTX / S&P 76.85% / 4.48% |
LoseVKTX / S&P VKTX unavailable / 5.68% |
LoseVKTX / S&P VKTX unavailable / 17.57% |
| 2017-Q20/3 |
LoseVKTX / S&P -26.03% / 3.09% |
LoseVKTX / S&P VKTX unavailable / 4.83% |
LoseVKTX / S&P VKTX unavailable / 17.74% |
| 2017-Q11/3 |
WinVKTX / S&P 22.69% / 6.07% |
LoseVKTX / S&P VKTX unavailable / 3.67% |
LoseVKTX / S&P VKTX unavailable / 13.32% |
| 2016-Q40/3 |
LoseVKTX / S&P -15.06% / 3.82% |
LoseVKTX / S&P VKTX unavailable / 2.09% |
LoseVKTX / S&P VKTX unavailable / 7.05% |
| 2016-Q31/3 |
WinVKTX / S&P 11.19% / 3.85% |
LoseVKTX / S&P VKTX unavailable / 0.20% |
LoseVKTX / S&P VKTX unavailable / -3.15% |
Dividend-reinvested, split-adjusted total return
1Y · 2025-08-29 to 2026-08-27
| Metric | VKTX total return | S&P 500 Total Return Index |
|---|---|---|
| Total return | 25.18% | 20.78% |
| Annualized return | 25.18% | 20.78% |
5Y · 2021-09-01 to 2026-08-27
| Metric | VKTX total return | S&P 500 Total Return Index |
|---|---|---|
| Total return | 383.71% | 83.14% |
| Annualized return | 37.06% | 12.86% |
10Y · 2016-09-01 to 2026-08-27
| Metric | VKTX total return | S&P 500 Total Return Index |
|---|---|---|
| Total return | 2504.62% | 319.30% |
| Annualized return | 38.54% | 15.41% |
Calculation rules
- window
- Latest 40 completed benchmark quarters; unavailable issuer evidence remains visible and scores 0.
- return Basis
- Issuer adjusted close reinvests distributions and normalizes splits; the S&P 500 Total Return Index is the direct benchmark.
- point Rule
- Strict same-quarter win = 1. Loss, tie or unavailable evidence = 0. No partial or subjective points.
- frequency
- Quarter endpoints only.
- fundamentals
- Trailing-four-quarter issuer revenue and EPS growth use the issuer's normalized government-filed facts.
- non Scoring
Snapshot captured 2026-09-04.
Similar stocks
| Stock Name | Country | Market Cap | PE Ratio |
|---|---|---|---|
| Indivior Pharmaceuticals, Inc. (INDV) | $4.250B | 14.09 | |
| Tango Therapeutics, Inc. (TNGX) | United States | $4.154B | -42.53 |
| Edgewise Therapeutics, Inc. (EWTX) | United States | $4.470B | -22.23 |
| AbCellera Biologics Inc. (ABCL) | $3.879B | -14.59 | |
| ACADIA PHARMACEUTICALS INC (ACAD) | United States | $3.823B | 11.45 |
| Veradermics, Inc (MANE) | United States | $4.839B | |
| Xenon Pharmaceuticals Inc. (XENE) | $3.684B | -14.27 | |
| Organon & Co. (OGN) | United States | $3.603B | 17.03 |
| IDEAYA Biosciences, Inc. (IDYA) | United States | $3.540B | -20.52 |
| Erasca, Inc. (ERAS) | United States | $5.073B | -19.96 |